Abstract
Actinobacillus pleuropneumoniae (App) and Mycoplasma hyopneumoniae (Mhp) cause porcine pleuropneumonia and mycoplasmal pneumonia, respectively, and have serious impacts on the swine industry because they retard the growth of pigs. To protect pigs against these diseases, we have developed a multivalent vaccine consisting of App bacterins, APP RTX toxins (Apx toxins), and Mhp bacterin and adhesin protein. This vaccine induced the production of higher levels of antibodies against App and Mhp than the commercial vaccine (Nisseiken Swine APM Inactivated Vaccine). Furthermore, the vaccine efficiently protected pigs against virulent App challenge, showing promise as an efficient vaccine for the prevention of two important respiratory diseases, porcine pleuropneumonia and mycoplasmal pneumonia.
Highlights
Actinobacillus pleuropneumoniae (App) is the causative agent of porcine pleuropneumonia, which affects the swine industry worldwide[1]
There is a strong demand for the development of multivalent vaccines against Mycoplasma hyopneumoniae (Mhp) and App, because these reduce the number of vaccinations and reduce the high labor costs of the vaccinations and the level of injectioninduced stress in pigs
In this study, we developed a promising multidisease vaccine and compared the immune responses and the protective efficacy it induced against Mhp and App infections in pigs with those induced by a commercial vaccine
Summary
Actinobacillus pleuropneumoniae (App) is the causative agent of porcine pleuropneumonia, which affects the swine industry worldwide[1]. Inactivated vaccines are safer than live-attenuated vaccines because they cannot revert to virulence and reduce the risk of recipients becoming carriers[4,5]. They can be combined with antigens from other pathogens to form multivalent vaccines to prevent infection with several pathogens. They are ecologically safe because they do not introduce live pathogens or live recombinant organisms to the environment[6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
